Compare PMTS & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | MGTX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.7M | 1.2B |
| IPO Year | 2015 | 2018 |
| Metric | PMTS | MGTX |
|---|---|---|
| Price | $28.38 | $13.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $27.67 | $24.57 |
| AVG Volume (30 Days) | 84.1K | ★ 459.3K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | 0.34 | ★ 1.30 |
| Revenue | ★ $312,189,000.00 | $81,391,000.00 |
| Revenue This Year | $9.95 | $141.38 |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | $84.41 | ★ $10.59 |
| Revenue Growth | 12.27 | ★ 144.57 |
| 52 Week Low | $10.81 | $6.62 |
| 52 Week High | $31.25 | $15.35 |
| Indicator | PMTS | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.60 | 66.09 |
| Support Level | $16.21 | $7.04 |
| Resistance Level | $31.25 | $15.35 |
| Average True Range (ATR) | 1.71 | 0.63 |
| MACD | 0.39 | 0.13 |
| Stochastic Oscillator | 72.58 | 85.62 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit segment, which principally produce secure debit and credit cards and provide card services for U.S. card-issuing financial institutions, including personalization, instant issuance and other payment solutions such as digital push provisioning for mobile wallets; Prepaid Debit, which provides secure packaging solutions, Prepaid Debit Cards, and other integrated prepaid card services to prepaid program managers in the U.S.; and other: principally corporate expenses. The firm generates key revenue from Debit and Credit segment.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.